Overview
International law firm McDermott Will & Emery advised AMILI, a Singapore-based precision gut microbiome startup, in raising US$10.5 million in its over-subscribed Series A funding led by Vulcan Capital.
Lead investor Vulcan Capital was joined by other new investors Pruksa Group, TVM Capital Healthcare, Emtek Group, Capital Code, SEEDS Capital, Pureland Group, Blue7 and returning investors GK Goh as well as other angel investors.
The funds will be used to strengthen AMILI’s position as Southeast Asia’s largest precision gut microbiome company, allowing it to expand rapidly in Southeast Asia and Greater Asia and further develop its proprietary microbiome analytics engine (AMILI PRIME).
AMILI is a precision gut microbiome company based in Singapore and serving the region. Through its proprietary analytics engine PRIME, AMILI develops diagnostics tests, predictive algorithms and microbiome-modifying interventions. Its consumer health arm, BIO & ME, utilises insights from AMILI’s database and PRIME to generate Asia-centric solutions towards personalised diets, supplementation and precision health.
The McDermott team advising AMILI was led by Singapore-based Counsel Dawn Tan, supported by Associate Anzhen Chng.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.